Pharming files rare disease drug leniolisib in Europe

Pharming has submitted its oral phosphoinositide 3-kinase delta (PI3Kδ) inhibitor leniolisib for approval in the EU as a treatment for activated PI3K delta syndrome (APDS), an ultra-rare di

Pharming preps filing for rare disease drug leniolisib after...

Pharming has taken a step closer to getting a second product to market, after its rare disease therapy leniolisib met its objectives in a pivotal trial, setting up regulatory filings in the

CSL preps filings for once-monthly antibody for HAE

Australia's CSL has said its one-monthly treatment for hereditary angioedema has shown it is safe and effective in a phase 3 trial, and will be filed for approval in its current financial y

CSL accuses ex-exec, now at Pharming, of stealing trade secr...

Pharming buys rare disease drug from Novartis for $20m

Pharming has bought a late-stage pipeline drug aimed at a rare disease of the immune system from Novartis for $20 million up front, plus other payments further down the line.

Dutch biotech Pharming plans to challenge big pharma in rare...

The introduction of Shire’s preventive treatment for hereditary angioedema has shaken up the market for drugs for this rare disease.